Cerus Corporation

Cerus Corporation

CERSNYSE / NASDAQHealthcareSmall cap

$1.85-$0.05 (-2.6%)

Last close · Data as of Nov 20, 2026

Market cap
$559.0M
Revenue
$206.1M
Net margin
-7.6%
ROCE
-4.7%

+24.2% over the last year

Cerus Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-19.9%
3M
-33.7%
6M
-31.2%
1Y
+24.2%
5Y
-74.3%

52-week range

Day change -$0.05 (-2.6%) from $1.90 to $1.85 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CERS, bought on each weekday since 2021.

News & filings

What Cerus filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 15.6 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 14.3% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Read moreShow less

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

Sector
Healthcare
Shares outstanding
192.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$559.0M
P/B
8.7x
EV / Sales
2.8x
P/S
2.7x
52-week high
$3.28
52-week low
$1.49

Profitability

Operating margin
-4.2%
Net margin
-7.6%
EBITDA margin
-2.7%
ROE
-24.3%
ROCE
-4.7%
ROIC
-3.9%
ROA
-7.0%
Asset turnover
0.93

Growth

Revenue
$206.1M
Revenue growth, 1Y
14.3%
Revenue CAGR, 3Y
8.4%
Net profit growth, 1Y
-25.3%
Free cash flow
$1.1M

Solvency

Current ratio
1.73
Debt / Equity
1.51
Debt / Assets
0.44
CFO / Net profit
-0.31
Cash / Market cap
14.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$206.1M
Cost of revenue$93.8M
Gross profit$112.3M
Operating expenses$121.0M
Research and development$67.7M
Selling, general and administrative$80.9M
Operating income-$8.7M
Interest and other-$6.6M
Pretax income-$15.3M
Tax and other$350.0k
Net income-$15.6M

Revenue and net profit

Revenue grew 14.3% in FY2025; net profit is the dashed line.

Cerus Corporation revenue and net profit by fiscal year
Cerus Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$162.0M-$42.8M
FY2023$156.4M-$37.5M
FY2024$180.3M-$20.9M
FY2025$206.1M-$15.6M

Cash flows

FY2025: $4.8M from operations, $1.1M free after investment (dashed).

Cerus Corporation operating and free cash flow by fiscal year
Cerus Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$25.6M-$27.6M
FY2023-$43.2M-$47.8M
FY2024$11.4M$8.5M
FY2025$4.8M$1.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$206.1M+14.3%1Y
EBITDA
-$5.5M
Net profit
-$15.6M
Cash from operations
$4.8M-57.4%1Y
Free cash flow
$1.1M-87.0%1Y
Revenue CAGR, 3Y
8.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$206.1M-$5.5M-$15.6M$1.1M-24.3%+14.3%-25.3%

Monthly returns

Month-by-month returns of CERS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$221.9M
Liabilities$156.9M
Equity$65.0M
Paid-in capital$1.1B
Retained earnings-$1.1B
Minority interest$740.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CERS highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Cerus Corporation (this company)2.8x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Cerus CorporationCERSthis company$559.0M—8.7x-24.3%—
Altimmune, Inc.ALT$567.9M-6.4x2.5x-39.2%-6.4x
Tactile Systems Technology, Inc.TCMD$567.7M29.7x2.6x8.7%12.4x
MiMedx Group, Inc.MDXG$563.0M11.6x2.2x18.9%5.3x
Rigel Pharmaceuticals, Inc.RIGL$559.7M1.5x1.4x93.8%4.4x
Ironwood Pharmaceuticals, Inc.IRWD$559.7M23.3x-2.1x-9.2%9.0x
Cytek Biosciences, Inc.CTKB$559.2M-8.4x1.6x-19.5%-28.3x
NeuroPace, Inc.NPCE$556.4M-25.9x29.2x-112.8%-50.2x
Fulgent Genetics, Inc.FLGT$553.8M-9.2x0.5x-5.4%-11.2x
Peer median—-2.5x1.9x-7.3%-1.0x

Year-to-date ROI

CERS since 1 January, against earlier years.

Historical volatility

CERS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Cerus Corporation operating margin by fiscal year
Cerus Corporation operating margin by fiscal year
DateOperating margin
FY2022-21.0%
FY2023-16.8%
FY2024-7.9%
FY2025-4.2%
LineFY2025
Cost of revenueCost Of Revenue$93.8M
Gross profitGross Profit$112.3M
Operating expensesOperating Expense$121.0M
Research and developmentResearch And Development$67.7M
Selling, general and administrativeSelling General And Administration$80.9M
Other operating expensesOther Operating Expenses-$27.7M
Total expensesTotal Expenses$214.8M
Pretax incomePretax Income-$15.3M

Learn while you research

Academy chapters picked for Cerus Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 1.51 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →